TEVA Stock News 50.53 05/14/2014 19:26:26 Teva Pharmaceutical

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Teva Pharmaceutical Industries Ltd (TEVA) 50.53 $TEVA

After Yesterday's Rally of 2.42% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue May 13, 3:54PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.10 to a high of $51.37. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $50.77 on volume of 4.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Teva Pharmaceutical Industries Set to Possibly Pullback After Yesterday's Rally of 2.42%
Comtex SmarTrend(R) - Tue May 13, 3:54PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $50.10 to a high of $51.37. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $50.77 on volume of 4.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023
M2 - Tue May 13, 10:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fs46lc/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. The pharmaceutical giant Novartis benefits a bit more from its recently announced partnership with Glaxo Smith Kline. The two drug makers will combine and among other transactions, Glaxo will buy Novartis's vaccine business and Novartis will gain Glaxo's oncology drug pipeline. Revenues of major pharma companies are broke out by these therapeutic areas in the report, Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023. Novartis has about 1/3 of its pharmaceutical revenues coming from oncology products. Thus it certainly makes sense to build that area, according to Kalorama's report. Novartis is currently number 2 in the world for cancer therapies behind Roche. The firm does not think that Novartis rises in market share from the deal, but it does believe it will certainly strengthen its position and maintain its wide distance from the 3rd competitor in the market. Although Kalorama also thinks the move benefits Glaxo Smith Kline, there could be less advantages for the company in the deal than for Novartis. Novartis will keep influenza vaccines, as part of the deal. This could work out to be highly beneficial, vaccines is a competitive area. The positions of companies do shift somewhat from year to year with vacillations in flu vaccines and other specific products, although for the past few years, Glaxo has led the market and Novartis has trailed at a distance. Furthermore, in pediatric vaccines GSK is also a major contributor and leader and solidifying this position is good but is not really helpful in the overall picture. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 estimates current sales for major pharmaceutical companies, breaks out revenue by therapeutic area and discusses general trends in the industry. Market watchers can use the report to understand developments in greater context than news media can provide. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 Top 25 Companies Mentioned - Abbvie, inc. - Actavis - Amgen, inc. - Astellas - Astra Zeneca plc - Baxter international - Bayer AG - Boehringer Ingelheim gmbh - Bristol-myers Squibb Company - Daiichi Sankyo - Eli Lilly and Company - Gilead Sciences - Glaxosmithkline PLC - Johnson & johnson - Merck & Co., inc. - Merck KGAA - Mylan - Novartis AG - Novo nordisk - Otsuka Pharmaceutical - Pfizer, inc. - Roche ltd. - Sanofi - Takeda Pharmaceutical co., LTD - Teva Pharmaceutical Industries, Ltd. For more information visit http://www.researchandmarkets.com/research/fs46lc/top_25

Teva Announces FDA Acceptance of sNDA Filing for Pediatric Indication for QNASL(R) (Beclomethasone Dipropionate) Nasal Aerosol
Business Wire - Tue May 13, 7:31AM CDT
Teva Pharmaceuticals Industries Ltd., (NYSE:TEVA) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for a lower dose QNASL(R) (beclomethasone dipropionate) Nasal Aerosol for the treatment of seasonal and perennial allergic rhinitis in children 4-11 years of age. QNASL is a waterless intranasal corticosteroid spray currently available for the treatment of nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in patients 12 years of age and older.

Analyzing the Global Generics Industry 2014-2017
M2 - Mon May 12, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wcrhxw/analyzing_the) has announced the addition of the "Analyzing the Global Generics Industry 2014" report to their offering. This in-depth analysis of the global generics industry includes an industry definition, historical development of the industry, industry statistics, value and volume analysis, industry segmentation by geography, amongst others. We analyze the issue of patent expiries by therapeutic areas in details, looking at what the impact is on the generic drugs market. We also look at the industry structure, market entry as well as research & development in the industry. A Porter's Five Forces Strategy analysis of the global generics industry is also included in the report. The impact of regulatory framework on the generics industry in Europe, Japan and the United States is analyzed in the report, along with the trends and challenges in the global generics industry. We also look at the popularity of small molecule generic drugs as well as the growing focus on biosimilars. Challenge of life cycle management strategies are also looked at. Global generics industry strategies are analyzed as well. An important aspect of the global generics market is the pricing and reimbursement of generic drugs in major markets. We analyze the pricing and reimbursement in the key markets of Australia, Austria, China, Czech Republic, France, Germany, Hungary, India, Italy, Japan, Norway, Poland, Romania, Spain, Sweden, the UK and the United States. Key Topics Covered: A. Executive Summary B. Analyzing the Global Generics Industry C. Global Generics Industry: Porter's Five Forces Strategy Analysis D. Regulatory Framework & Impact on the Generics Industry E. Industry Trends & Challenges F. Industry Strategies G. Global Generics Industry: Analysis of Major Markets H. Pricing and Reimbursement of Generics: An Analysis by Major Markets I. Global Generics Industry Forecast J. Major Industry Players - Actavis - Apotex - Bayer AG - Biogaran S.A.S. - China Grand Pharmaceutical and Healthcare Holdings Limited - Daiichi Sankyo Co., Ltd. - Dr. Reddy's Laboratories Limited (DRL) - Esteve Group - Hospira Inc - Lupin - Mylan Inc. - Nichi-iko Pharmaceutical - Novartis AG - Par Pharmaceutical Companies, Inc. - Perrigo Company PLC - Ratiopharm Group - STADA Arzneimittel AG - Sandoz - Sanofi - Sawai Pharmaceutical Co., Ltd - Teva Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/wc...lyzing_the

Is This The Next Billion-Dollar Biotech Idea?
Todd Campbell, The Motley Fool - Motley Fool - Sun May 11, 9:30AM CDT
Developing a new drug costs hundreds of millions of dollars, but for every five drugs that reach the market, another 95 end up in the trash bin .  That makes finding the next big thing in biotech particularly hit or miss. Frankly, the odds are...

Teva Pharmaceutical Industries Falls 1.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri May 09, 4:00PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $48.81 to a high of $50.13. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $49.29 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Teva Pharmaceutical Industries Set to Possibly Rebound After Yesterday's Selloff of 1.46%
Comtex SmarTrend(R) - Fri May 09, 4:00PM CDT
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $48.81 to a high of $50.13. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $49.29 on volume of 3.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Positive Medicines Board Opinion, Stock Price Updates, Drug Approval, Dividend Announcement, and Settlement of Claims - Analyst Notes on Allergan, Amgen, Teva, Lilly and Medtronic
PR Newswire - Fri May 09, 10:30AM CDT
Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Amgen Inc. (NASDAQ: AMGN), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), Eli Lilly and Co. (NYSE: LLY) and Medtronic Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2265-100free.

Teva to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Business Wire - Fri May 09, 7:00AM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will host a live audio webcast at the Bank of America Merrill Lynch 2014 Health Care Conference. Eyal Desheh, EVP & CFO will present on Tuesday, May 13, 2014 at 12:00 PM PT.

Teva Announces COPAXONE(R) Recognized as "Brand of the Year" by Pharmaceutical Executive Magazine
Business Wire - Thu May 08, 7:01AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that COPAXONE(R) (glatiramer acetate injection), the #1 global therapy for relapsing multiple sclerosis, has been named the 2014 "Brand of The Year" by Pharmaceutical Executive Magazine, a leading print and online publication for the biopharmaceutical industry.

Growth Hormone Deficiency - Pipeline Review, H1 2014: 24 Companies and 23 Drugs Profiled
M2 - Thu May 08, 3:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jdp2w7/growth_hormone) has announced the addition of the "Growth Hormone Deficiency - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Growth Hormone Deficiency, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Growth Hormone Deficiency and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Growth Hormone Deficiency - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Growth Hormone Deficiency and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Growth Hormone Deficiency products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects Companies Involved: - Access Pharmaceuticals, Inc. - Aileron Therapeutics, Inc. - Ambrx, Inc. - Ascendis Pharma A/S - Biogenomics - Bolder Biotechnology, Inc. - Braasch Biotech LLC - CJ CheilJedang Corp. - Critical Pharmaceuticals Limited - Delpor, Inc. - Emisphere Technologies, Inc. - Flamel Technologies S.A. - HanAll Biopharma Co., Ltd. - Inbiopro Solutions Pvt. Ltd. - LG Life Sciences, Ltd. - OPKO Health, Inc. - Pfenex Inc. - Phage Pharmaceuticals, Inc. - PharmaEssentia Corporation - SynBio LLC - Teva Pharmaceutical Industries Limited - Theratechnologies Inc. - Versartis, Inc. - XL-protein GmbH Drug Profiles: - somatropin SR - MOD-4023 - tesamorelin acetate - MOD-4023 - ARX-201 - ACP-001 - TV-1106 - SYN-20100504RU - somatropin - HL-032 - somatropin - ALRN-5281 - somatropin biobetter - CP-016 - CobOral hGH - BBT-031 - somatropin biosimilar - IBPB-003-HH - somatropin biosimilar - Vaccine For Growth Hormone Deficiencies - xl-020 - CJ-40002 - Pegylated Growth Hormone For more information visit http://www.researchandmarkets.com/research/jd...th_hormone

Is Abbott Laboratories Headed for a Breakup?
Dan Carroll, The Motley Fool - Motley Fool - Wed May 07, 5:30PM CDT
Dealing's back in style in health care's 2014. From major drugmakers looking to sell off slow-growth assets to big pharma's top names hunting for blockbuster acquisitions, the year's been home to no shortage of activity on the mergers and...

The Biggest Biotech Catastrophes of the Week
Cory Renauer, The Motley Fool - Motley Fool - Wed May 07, 1:30PM CDT
Last week was rough for clinical stage biotechnology companies. Three watched their market caps dissolve after reporting lead candidate failures. Endocyte had an abrupt reversal of fortune, while  OncoGenex Pharmaceuticals   found out its...

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing

Narrower-than-Expected Loss at Momenta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 11:10AM CDT
Momenta Pharma (MNTA) reported 1Q14 net loss per share of 53 cents, narrower than the Zacks Consensus Estimate of a loss of 55 cents

Drug Addiction - Pipeline Review, H1 2014: 17 Company and 34 Drugs Profiled
M2 - Wed May 07, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp6lcx/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Addex Therapeutics - Alkermes Plc - Aphios Corporation - Biotie Therapies Corp. - Camurus AB - Curemark, LLC - D&A Pharma SAS - Embera NeuroTherapeutics, Inc. - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lightlake Therapeutics Inc. - LondonPharma Ltd - Omeros Corporation - Rottapharm|Madaus - SK Biopharmaceuticals Co., Ltd. - Savant HWP, Inc. - Teva Pharmaceutical Industries Limited Drug Profiles: - nepicastat hydrochloride - ibudilast - buprenorphine hydrochloride - SKL-N05 - Butyrylcholinesterase - candesartan cilexetil - baclofen ER - ketamine hydrochloride - (oxazepam metyrapone) - (samidorphan buprenorphine hydrochloride) - LT-22 - ASB - methadone - dronabinol - ADX-88178 - ADX-71441 - OMS-527 - Vaccine For Cocaine Addiction - Cocaine Addiction Vaccine - MH-6 Vaccine - MH-2 [R] Vaccine - Ibogaine Analog - 5HT2 Modulators for CNS and Metabolic Disorders - CM-1212 - methoxycoronaridine - ICKLH-SMO9 Vaccine - N-acetylcystein MGluR5 Antagonist - CR-5542 Series - Small Molecules to Inhibit DAT and SERT for CNS Disorders - Triazole Compounds For more information visit http://www.researchandmarkets.com/research/sp..._addiction

Huntington's Disease - Pipeline Review, H1 2014: 50 Company and 93 Drug Profiles
M2 - Wed May 07, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v2bgc4/huntingtons) has announced the addition of the "Huntington's Disease - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Huntington's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Huntington's Disease and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - GAcadia Pharmaceuticals Inc. - Accera, Inc. - Alnylam Pharmaceuticals, Inc. - Angita B.V. - Aniona ApS - Auspex Pharmaceuticals, Inc. - Azevan Pharmaceuticals, Inc. - BioCrea GmbH - Centre de Regulacio Genomica - Chronos Therapeutics Limited - Cortex Pharmaceuticals, Inc. - CrystalGenomics, Inc. - EncephRx, Inc. - Evotec AG - GW Pharmaceuticals plc - Galenea Corp. - Suven Life Sciences Ltd. - Teva Pharmaceutical Industries Limited - Treventis Corporation - Trophos SA - UniQure BV - Valens Therapeutics, Inc. - Varinel, Inc. - Vertex Pharmaceuticals Incorporated - VivaCell Biotechnology Espana S.L. - Vybion, Inc. - Wellstat Therapeutics Corporation - enzyme Corporation - iPierian, Inc Drug Profiles: - pridopidine - SD-809 ER - Coenzyme Q10 - cysteamine DR - PF-02545920 - nabiximols - selisistat - PBT-2 - Epigallocatechin Gallate - BN-82451 - SOM-3355 - OMS-824 - SRX-251 - SRX-246 - SUVN-502 - GSK-356278 - uridine triacetate - Lithium citrate - ALN-HTT - CERE-120 - INDUS-815C - AC-0523 - Xpro-1595 - AN-726 - CX-929 - VAR-10300 - AMT-090 - noscapine - NsG-33 - MTP-131 For more information visit http://www.researchandmarkets.com/research/v2...untingtons

Neuroblastoma Pipeline Review 2014: 32 Companies & 73 Drug profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pzz2k/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - United Therapeutics Corporation - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Celgene Corporation - AEterna Zentaris Inc. - Lixte Biotechnology Holdings, Inc. - Lorus Therapeutics Inc. - Novogen Limited - Threshold Pharmaceuticals, Inc. - Sareum Holdings plc - MabVax Therapeutics, Inc. - Bionucleon Srl - CerRx, Inc. - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - APEIRON Biologics AG - Xcovery, Inc. - Sutro Biopharma, Inc. - Incuron, LLC - Errant Gene Therapeutics, LLC - DEKK-TEC, Inc. - Bexion Pharmaceuticals, LLC. - Cancer Prevention Pharmaceuticals, Inc. - CureFAKtor Pharmaceuticals. LLC For more information visit http://www.researchandmarkets.com/research/9p...roblastoma

Substance (Drug) Abuse - Pipeline Review, H1 2014: Includes 10 Company and 31 Drug Profiles
M2 - Wed May 07, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rb6x74/substance_drug) has announced the addition of the "Substance (Drug) Abuse - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Substance (Drug) Abuse, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Substance (Drug) Abuse and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Addex Therapeutics - Adial Pharmaceuticals, LLC - AllTranz, Inc. - Foresee Pharmaceuticals, LLC - Grunenthal GmbH - InterveXion Therapeutics LLC - Reckitt Benckiser Pharmaceutical, Inc. - Rottapharm|Madaus - Snowdon Inc. - Teva Pharmaceutical Industries Limited Drug Profiles: - acetylcysteine - lithium carbonate - acetylcysteine - Icariin - nabilone - neboglamine - aripiprazole - doxazosin mesylate - lisdexamfetamine dimesylate - naltrexone - carvedilol phosphate - acetylcysteine - buspirone hydrochloride - RBP-8000 - hydrocodone bitartrate ER - aripiprazole - ondansetron - Ch-mAb7F9 - L-Tetrahydropalmatine - lisdexamfetamine dimesylate - ADX-88178 - ADX-71441 - Program For Neurological Disorders - ADX-71743 - Vaccine For Drug Abuse - Mutated CocE Polypeptides - Anti-METH Vaccine - Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - VU-0463841 For more information visit http://www.researchandmarkets.com/research/rb...tance_drug
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 258

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 334

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 333

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 282

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 546

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 461

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 466

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 289

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 411

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 335

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Apple Inc. Announces Record Q4 Results and Product Launches

Updated Category News Views 236

Apple Achieves Remarkable Fourth Quarter Results Apple Inc. has announced its financial performance for the fourth quarter of its fiscal year 2024, showcasing stellar results that reflect the company's growth and expansion in the tech industry. The tech giant reported quarterly revenue hitting a staggering $94.9 billion, which represents a 6% increase compared to the...

Continue Reading
China-Russia Culture Fair Boosts Jiamusi, Heilongjiang

Updated Category News Views 100

Jiamusi: A Cultural Crossroad in Northeast China Imagine this: Jiamusi, nestled in the embrace of Heilongjiang Province, stepping into the spotlight as it co-hosts the 16th China-Russia culture fair. This northeast city isn't just another dot on the map. It's gearing up to be a hub of cultural buzz, packed with ties that go beyond borders. From July through September,...

Continue Reading
Unlocking Sustainability in Broadband Using Existing Networks

Updated Category News Views 176

Unlocking Sustainability in Broadband Using Existing Networks LUND, Sweden — InCoax Networks has introduced a groundbreaking whitepaper addressing the modernization of broadband infrastructure in multi-dwelling units (MDUs). This initiative is not only cost-effective but also significantly improves the environmental impact associated with deploying broadband services....

Continue Reading
Interlink Electronics Secures NASA Grant for Air Quality Solutions

Updated Category News Views 174

Interlink Electronics Receives Significant Funding from NASA Recognizes Company's leading position in gas sensor research and commercialization Interlink Electronics, Inc. (NASDAQ: LINK), a premier provider of innovative sensors and electronic solutions, has received a significant boost with a $150,000 award from NASA. This funding is designated for the development of...

Continue Reading
Burford Capital Set to Reveal 3Q24 Financial Insights Soon

Updated Category News Views 154

Burford Capital Set to Release 3Q24 Financial Results Burford Capital Limited, renowned for its leadership in finance and asset management focused on legal services, has announced the date for its financial results. The firm is poised to share critical insights regarding its performance for the three and nine months ending September 30, 2024. Details of the Financial...

Continue Reading